COVID-19: Loss of bridging between innate and adaptive immunity?


Journal

Medical hypotheses
ISSN: 1532-2777
Titre abrégé: Med Hypotheses
Pays: United States
ID NLM: 7505668

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 17 04 2020
revised: 08 05 2020
accepted: 21 05 2020
pubmed: 7 6 2020
medline: 23 12 2020
entrez: 7 6 2020
Statut: ppublish

Résumé

COVID-19 has spread to most countries in the world. However, there are some striking differences in how COVID-19 is behaving in different age groups. While data on COVID-19 is limited, children appear to be less susceptible to severe disease. These unique characteristics may be considered as a potential link to understanding the immune system and response in COVID-19 and lead to an effective cure to the disease. We suggest a possible role of loss of bridging between innate and adaptive immunity in COVID-19 and a potential treatment modality also discussed.

Identifiants

pubmed: 32505066
pii: S0306-9877(20)30863-X
doi: 10.1016/j.mehy.2020.109861
pmc: PMC7245229
pii:
doi:

Substances chimiques

Cytokines 0
Interferons 9008-11-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109861

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

Age (Dordr). 2011 Sep;33(3):363-76
pubmed: 20953722
J Gen Virol. 2009 Nov;90(Pt 11):2686-2694
pubmed: 19625461
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Acta Paediatr. 2020 Jul;109(7):1497-1498
pubmed: 32279351
Front Immunol. 2019 Jul 24;10:1736
pubmed: 31396233
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Immunol. 2007 Jun 1;178(11):6912-22
pubmed: 17513740
J Clin Immunol. 2010 May;30(3):373-83
pubmed: 20182777
J Med Virol. 2020 Sep;92(9):1615-1628
pubmed: 32356908

Auteurs

Vishal U S Rao (VUS)

Department of Head and Neck Oncology, HCG Cancer Hospital, Bengaluru, Karnataka, India. Electronic address: drvishal.rao@hcgel.com.

Gururaj Arakeri (G)

Department of Head and Neck Oncology, HCG Cancer Hospital, Bengaluru, Karnataka, India.

Anand Subash (A)

Department of Head and Neck Oncology, HCG Cancer Hospital, Bengaluru, Karnataka, India.

Jyothsna Rao (J)

iCREST, International Stemcell Services Ltd., HealthCare Global Enterprises Ltd., Bengaluru, Karnataka, India.

Sachin Jadhav (S)

Department of Hematology, Immunology and Medical Oncology, HCG Cancer Hospital, Bengaluru, Karnataka, India.

Mufti Suhail Sayeed (M)

Department of Translational Medicine and Therapeutics, HCG Cancer Hospital, Bengaluru, Karnataka, India.

Gururaj Rao (G)

iCREST, International Stemcell Services Ltd., HealthCare Global Enterprises Ltd., Bengaluru, Karnataka, India.

Peter A Brennan (PA)

Department of Oral & Maxillofacial Surgery, Queen Alexandra Hospital, Cosham, Portsmouth, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH